DGAP-News: Proteo Biotech AG / Schlagwort(e):
Sonstiges/Zwischenbericht
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug
Designation to Elafin for the treatment of pulmonary arterial
hypertension
10.01.2013 / 11:30
———————————————————————
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation
to Elafin for the treatment of pulmonary arterial hypertension
Irvine, CA – Kiel, January 10, 2013 – Proteo, Inc. (OTCQB
DGAP-News: Proteo Biotech AG / Schlagwort(e): Studie
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin
in Coronary Bypass Surgery (EMPIRE Study)
11.12.2012 / 12:45
———————————————————————
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in
Coronary Bypass Surgery (EMPIRE Study)
75% of patients enrolled – Approval for EMPIRE sub-study
Irvine, CA – Kiel, December 11, 2012 – Proteo, Inc. (OTCQB: PTEO) and its
DGAP-News: Proteo Biotech AG / Schlagwort(e): Research Update/Studie
Proteo, Inc. / Proteo Biotech AG: Major advances in the elafin
development program for lung diseases – NIH supports research on
Elafin with a $10.8 million grant
06.12.2011 / 11:44
———————————————————————
Proteo, Inc. / Proteo Biotech AG:
Major advances in the elafin development program for lung diseases – NIH
supports research on Elafin with a $10.8 million grant
